• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Stronger Statin Use OK in Patients After ACS

Article

A high-dose statin therapy for a post-acute coronary syndrome patient appears to produce no higher risk of kidney injury than a low-dose regimen. Study findings may reassure clinicians that high-potency statins are safe for patients after ACS. MedPage Today reports:

For post-acute coronary syndrome patients, high-dose statin therapy appeared to produce no higher a risk of kidney injury than a low-dose regimen, according to preliminary subanalyses of two randomized trials.

There were no differences between patients taking either 40 or 80 mg of a statin in creatinine elevations of >1.5, >2.0, and >3.0 mg/dL in the PROVE IT-TIMI 22 randomized trial, according to Amy Sarma, MD, MHS, of Brigham and Women's Hospital in Boston, and colleagues.

Similarly, in the A-to-Z Trial, researchers found no statistical differences in creatinine elevation at the same three increased levels between patients receiving 20 mg or 40 mg of statin therapy, Sarma reported during the American Heart Association's Emerging Science Series webinar.

Read the full story here: http://bit.ly/12ep1os

Related Videos
Video 6 - "Closing Thoughts on the Current Ovarian Cancer Treatment Landscape"
Video 5 - "Harnessing Biomarkers & Molecular Profiling in Ovarian Cancer Treatment"
Video 7 - "Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients"
Video 6 - "Current Front-Line Targeted Treatments in Ph+ ALL"
Video 6 - "Community Partnership: Increasing Public Awareness of CVD"
Video 5 - "Peripheral Arterial Disease Awareness for Minority Populations"
Screenshot of Jennifer Vaughn, MD, in a Zoom video interview
dr amy paller
Shawn Kwatra, MD, dermatologist, John Hopkins University
Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients with Plaque Psoriasis
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.